Blog

RSS Feed
Posted by Michael Wonder on 10 Jul 2024

Pharma company lawsuit forces Dutch health agency to reassess cancer drug

9 July 2024 - The Dutch healthcare procurement agency has said it will reassess the breast cancer drug abemaciclib after ...

Read more →
Posted by Michael Wonder on 01 May 2023

Dutch Ministry Of Health will not reimburse Gilead’s breast cancer drug, Trodelvy

1 May 2023 - Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not ...

Read more →
Posted by Michael Wonder on 09 Mar 2019

Dutch join backlash at expensive drugs by making their own

8 March 2019 - In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass ...

Read more →
Posted by Michael Wonder on 05 Mar 2019

Determining the comparative value of pharmaceutical risk-sharing policies in non–small cell lung cancer using real-world data

2 March 2019 - Risk-sharing arrangements can be used to mitigate uncertainty about the value of a drug by sharing the ...

Read more →
Posted by Michael Wonder on 24 Apr 2017

Managed entry agreements for oncology drugs: lessons from the European experience to inform the future

4 April 2017 - The aim of this study was to conduct an analysis on the regulation and application of ...

Read more →